| 12/08 | Novartis bestätigt Todesfälle nach Behandlung mit Gentherapie |  |
| 12/08 | Novartis confirme deux décès liés à sa thérapie génique Zolgensma |  |
| 12/08 | Novartis bestätigt Todesfälle nach Behandlung mit Gentherapie Zolgensma | |
| 04/08 | El fármaco contra el Alzheimer de Lilly podría obtener una rápida aprobación de la FDA .. |  |
| 04/08 | Eisai presents new findings on lecanemab's investigational subcutaneous formulation and.. |  |
| 28/07 | The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BII.. | |
| 28/07 | The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BII.. | |
| 27/07 | Biogen Inc. - FDA Accepts Biogen's New Drug Application and Grants Priority Review of T.. | |
| 26/07 | Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi.. | |
| 26/07 | Biogen Says US FDA Accepts NDA, Grants Priority Review for Amyotrophic Lateral Sclerosi.. | |
| 26/07 | U.S. FDA accepts Biogen's ALS therapy for review | |
| 26/07 | U.S. FDA grants priority review to Biogen's ALS drug | |
| 26/07 | FDA Accepts Biogen's New Drug Application and Grants Priority Review of Tofersen for a .. | |
| 26/07 | Biogen Inc. Announces FDA Accepts its New Drug Application and Grants Priority Review o.. | |
| 26/07 | Biogen Gets FDA Priority Review of Tofersen in Rare Form of ALS | |
| 25/07 | Novartis-Tochter Sandoz kommt mit Antrag für MS-Biosimilar voran | |
| 25/07 | NOVARTIS : demande d'homologation évaluée pour natalizumab de Sandoz | |
| 21/07 | Growth stocks are back in favor | |
| 21/07 | USA-Les valeurs à suivre à Wall Street (actualisé) | |
| 21/07 | ANALYST RECOMMENDATIONS : Tesla, Nike, Netflix, Idexx Laboratories, Biogen... | |
| 21/07 | WALL STREET : rebond prolongé, même sans catalyseurs | |
| 20/07 | US Stocks Close Higher Wednesday, Led by Consumer Discretionary, Tech | |
| 20/07 | BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF.. | |
| 20/07 | US Stocks Close Higher Wednesday Despite Steeper-Than-Expected Existing-Home Sales Decl.. | |
| 20/07 | Biogen Faces Declining Sequential Revenue Despite Positive Q2 Results, Wedbush Says | |
| 20/07 | Health Care Down as Biogen, Merck Retreat -- Health Care Roundup | |
| 20/07 | BIOGEN : Reports Second Quarter 2022 Results - Form 8-K/A | |
| 20/07 | Biogen Shares Decline After Company Reports Lower Q2 Profits, Revenue | |
| 20/07 | Investors take a wait-and-see attitude ahead of central bank meetings | |
| 20/07 | Les valeurs à suivre aujourd'hui à Wall Street - Mercredi 20 juillet 2022 | |
| 20/07 | Biogen chops expenses in Q2, raises 2022 profit forecast | |
| 20/07 | Biogen double son bénéfice par rapport au premier trimestre | |
| 20/07 | AKTIEN NEW YORK AUSBLICK : Knappe Verluste erwartet - Netflix überzeugt | |
| 20/07 | Biogen says aiming to build commercial infrastructure for alzhei… | |
| 20/07 | BIOGEN : relèvement des objectifs pour 2022 | |
| 20/07 | Pharmakonzern Biogen erhöht Jahresziele - Zweites Quartal besser als befürchtet | |
| 20/07 | Biogen says co continues to enforce its patents, but biosimilar… | |
| 20/07 | Biogen says partner eisai plans to file for traditional approval… | |
| 20/07 | TRANSCRIPT : Biogen Inc., Q2 2022 Earnings Call, Jul 20, 2022 | |
| 20/07 | Biogen Reports Lower Q2 Profits, Revenue | |
| 20/07 | BIOGEN : Reports Second Quarter 2022 Results 582.7 KB | |
| 20/07 | BIOGEN : Reports Second Quarter 2022 Results | |
| 20/07 | BIOGEN : Reports Second Quarter 2022 Results - Form 8-K | |
| 20/07 | Biogen leans on new Alzheimer's drug to calm investor worries | |
| 20/07 | Biogen profit more than doubles on Samsung Bioepis stake sale | |
| 20/07 | BIOGEN : Q2 2022 Biogen Earnings Presentation | |
| 20/07 | BIOGEN : Reports Q2 2022 Earnings | |
| 20/07 | Biogen Inc. Updates Earnings Guidance for Full Year 2022 | |
| 20/07 | Biogen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 3.. | |
| 20/07 | Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020. | |
| 20/07 | USA-Les valeurs à suivre à Wall Street (actualisé) | |
| 20/07 | MARKETMIND : Weapons of war | |
| 20/07 | Reuters-schedule/… | |
| 18/07 | GLOBAL MARKETS LIVE : Boeing, Gazprom, HSBC, Bank of America, Goldman Sachs... | |
| 18/07 | The calm before the storm? | |
| 18/07 | USA-Les valeurs à suivre à Wall Street (actualisé) | |
| 07/07 | Japan Index Recuperates; V Cube Shares Rally 5% | |
| 06/07 | BIOGEN : to Report Second Quarter 2022 Financial Results July 20, 2022 | |
| 06/07 | Eisai Co., Ltd. - THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS.. | |
| 06/07 | Biogen, Eisai Get FDA Priority Review for Alzheimer's Treatment Lecanemab | |
| 06/07 | Eisai Gets US Priority Review for Alzheimer's Drug | |
| 06/07 | Japan's Nikkei falls on slowdown worries, energy losses | |
| 06/07 | Japanese shares fall on energy rout, economic slowdown fears | |
| 06/07 | Eisai Shares Rise Sharply After U.S. FDA Grants Priority Review for Potential Alzheimer.. | |
| 06/07 | The u.s. fda accepts and grants priority review for eisai's biologics license applicati.. | |
| 06/07 | Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted th.. | |
| 03/07 | Les multinationales américaines aux prises avec l'envolée du dollar | |
| 24/06 | Biogen Terminates Alzheimer's Drug Aduhelm Study Over Coverage Limits | |
| 24/06 | BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Value Index | |
| 24/06 | BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Value Index | |
| 24/06 | BIOGEN INC.(NASDAQGS : BIIB) dropped from Russell Top 200 Index | |
| 24/06 | BIOGEN INC.(NASDAQGS : BIIB) added to Russell Midcap Index | |
| 22/06 | Biogen, Happify Health Team Up to Offer Digital Services for Multiple Sclerosis Patient.. | |
| 22/06 | Biogen Inc. - European Patent Office Grants Patent Related to TECFIDERA (Dimethyl Fumar.. | |
| 22/06 | Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital.. | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Rapport
